SCHEMBL16749064

SCHEMBL16749064

CC1(C)CC(c2ccc(C3CC(C)(C)NC(C)(C)C3)c(F)c2)CC(C)(C)N1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.37
KDM1A O60341 2/20 0.33
ALDH1A1 P00352 2/20 0.32
OPRL1 P41146 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
CYP11B2 P19099 1/20 0.31
RCOR1 Q9UKL0 1/20 0.31
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30
PKM P14618 1/20 0.30
ALOX15 P16050 1/20 0.30
ALOX12 P18054 1/20 0.30
RAD52 P43351 1/20 0.30
GFER P55789 1/20 0.30
CHRNB2 P17787 1/20 0.30
ADRA2C P18825 1/20 0.30
CHRNB4 P30926 1/20 0.30
CHRNA3 P32297 1/20 0.30
CHRNA7 P36544 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16749128 0.94 L3MBTL1 (0.34) L3MBTL1KDM1AALDH1A1OPRL1
SCHEMBL16749045 0.88 L3MBTL1 (0.34) L3MBTL1KDM1AALDH1A1MAPT
SCHEMBL18931540 0.85 L3MBTL1 (0.33) L3MBTL1
SCHEMBL18931556 0.85 L3MBTL1 (0.35) L3MBTL1KDM1AALDH1A1MEN1KMT2A
SCHEMBL20126324 0.85 HCRTR2 (0.34) L3MBTL1ALDH1A1OPRL1
SCHEMBL20126345 0.85 OPRL1 (0.38) L3MBTL1KDM1AALDH1A1OPRL1RCOR1
SCHEMBL16749130 0.85 L3MBTL1 (0.38) L3MBTL1ALDH1A1OPRL1MEN1KMT2A
SCHEMBL20126212 0.84 HTR2C (0.38) L3MBTL1MEN1KMT2ALMNA
SCHEMBL16749143 0.84 OPRL1 (0.42) OPRL1
SCHEMBL16749132 0.83 OPRL1 (0.30) L3MBTL1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160289189-A1 PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC CORPORATION (JP) 2016-10-06 US disclosed
US-20160289189-A1 PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC CORPORATION (JP) 2016-10-06 US disclosed
EP-3072885-A1 PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC Corporation (JP) 2016-09-28 EP disclosed
WO-2015076077-A1 PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC株式会社 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160289189-A1 PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT PLD1, DRD1, CCND1 L3MBTL1 878/4885KDM1A 635/4885ALDH1A1 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.